<DOC>
	<DOCNO>NCT01695707</DOCNO>
	<brief_summary>Many patient eczema ( atopic dermatitis ) inherent defect skin barrier demonstrate high water loss . In laboratory condition , study show pioglitazone restore skin barrier function skin eczema patient . The purpose study determine take pioglitazone improve skin barrier function people eczema .</brief_summary>
	<brief_title>Assessing Impact Pioglitazone Skin Barrier Function Atopic Dermatitis Patients</brief_title>
	<detailed_description>Enrolled patient randomize either placebo pioglitazone . Each randomize subject skin biopsy skin irritancy assay perform prior treatment end 12 week treatment . Noninvasive barrier measurement include transepidermal water loss record study visit .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>. Moderate Severe AD : EASI ≥ 10 ii . Active Atopic Dermatitis : Subjects must within last 3 month accord medical record medical exam investigator : Pruritus Eczema ( acute , subacute , chronic ) I . Typical morphology agespecific pattern Patterns include ( 1 ) facial , neck , extensor involvement infant child , ( 2 ) current prior flexural lesion age group , ( 3 ) spar groin axillary region . II . Chronic relapse history iii . Extrinsic must also meet follow : serum total IgE ≥ 1.5 S.D . great agematched norm positive multiallergen RAST ( Phadiatop ) . Additionally , subject must TEWL nonlesional skin upper arm ≥ 8 gm/m2/h screen visit . This ensure fact study subset AD subject skin barrier defect . Unwillingness inability complete Informed Consent process Subjects history keloid formation History lidocaine Novocain allergy Subjects systemic infection require course systemic antibiotic antiviral within last 2 week Subjects MD diagnose Type 1 2 diabetes mellitus Subjects NYHA class III IV cardiac status Subjects history liver disease ( EtOH , viral hepatitis , druginduced hepatitis ) Subjects evidence underlie systemic disease base history physical ( diagnostic category ( associate allergic disorder ) , wellcontrolled hypertension , hyperlipidemia ) . History cancer nonmelanomatous skin cancer cervical dysplasia Participants enrol systemic treatment atopic dermatitis ( e.g . cyclosporine , mycophenolate mofetil ) must remain stable dose duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>eczema</keyword>
</DOC>